Resolutions from Sobi’s Annual General Meeting

The Swedish Orphan Biovitrum AB (publ) (Sobi) Annual General Meeting (AGM) convened earlier today in Stockholm and voted in favour of the resolutions proposed at the meeting, including: Adoption of the profit and loss statements and balance sheet and discharge of liability The AGM adopted the income statements and the balance sheets and approved the proposal to carry forward the retained profits of SEK 4,561,601,316 . The board members and the chief executive officer were discharged from liability for the financial year 2014. Election of Board of Directors, remuneration to the Directors and election of Auditor The ordinary board members Adine Grate…

BioLight Obtains EU CE Mark for CellDetect® Non-Invasive Test for Detecting Recurrence of Bladder Cancer

Core European Patent Granted For CellDetect® TEL-AVIV, Israel, June 30, 2015 /PRNewswire/ — BioLight Life Sciences Investments Ltd. (OTC: BLGTY, TASE:BOLT), a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, announced today that its CellDetect® non-invasive test for detecting bladder cancer in urine has obtained CE Marking, enabling the product to be marketed and sold in Europe and other territories. The CE marking recognizes the conformity of the CellDetect® non-invasive test for detecting recurrence of bladder cancer in urine with the relevant directive of the European Community. BioLight also announced that the European Patent Office has…

Clinical Studies of Disease-Modifying Therapies & Drug Delivery Candidates Lead to New Drug Therapies & Patents for Treating Patients with Parkinson’s Disease & Other Neurodegenerative Disorders

CORAL SPRINGS, Florida, June 30, 2015 /PRNewswire/ — Over one million Americans suffer from the tremors, stiffness and slurred speech of Parkinson’s disease and medications are usually the first-line treatment for this and other neurological conditions.  Biopharmaceutical & Biotech companies continue to research through clinical studies to identify diagnostics and develop treatments designed to transform the lives of patients with severe diseases and other rare orphan conditions.  Biotech companies in the news are:  Amarantus BioScience Holdings, Inc. (OTC:AMBSD), Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS),  ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD),  Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) and Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) Amarantus BioScience Holdings,…

“German Gruendlichkeit”: COMPUTER BILD Launches TESTGARAGE.com

BERLIN and LOS ANGELES, June 30, 2015 /PRNewswire/ — COMPUTER BILD is Europe’s most influential, most successful tech website. Almost 20 million German speaking Europeans consult the COMPUTER BILD website or magazine every month for the latest news on tech, thorough reviews and independent lab tests.  Now the media brand takes this success to a whole new level and proudly announces TESTGARAGE.com. The new English-speaking website TESTGARAGE.com is COMPUTER BILD’s first overseas experiment. The brand-new website features independent, extensive product tests of smartphones, tablets, computers, cars and digital lifestyle products, which is constantly adjusted to consumer needs and newly introduced product categories. In…

Genesys Named a Leader in the 2015 Gartner Magic Quadrant for Contact Center Infrastructure

DUBAI, UAE, June 30, 2015 /PRNewswire/ — Genesys Positioned in the Leaders Quadrant for the Seventh Consecutive Year Genesys (http://www.genesys.com), the market leader in omnichannel customer experience (CX) and contact center solutions, today announced that the company has been positioned as a market leader in the “Magic Quadrant for Contact Center Infrastructure, Worldwide”[1] report by Gartner, Inc. This is the seventh consecutive year that Genesys has been named a leader for contact center infrastructure. Gartner also named Genesys the furthest for “completeness of vision” for the seventh consecutive year.      (Photo: http://photos.prnewswire.com/prnh/20150630/226953 ) The annual Gartner Magic Quadrant report evaluates contact center vendors on their completeness…

Yext Names Jeffrey K. Rohrs as Chief Marketing Officer

Salesforce and ExactTarget Veteran to Help Power New Phase of Growth NEW YORK, June 30, 2015 /PRNewswire/ — Yext, the global Digital Presence Management (DPM) leader, announced today the addition of Jeffrey K. Rohrs as its Chief Marketing Officer (CMO). Rohrs will spearhead Yext’s global brand strategy, field marketing expansion, and demand generation initiatives as the company looks to build upon the success of its PowerListings™ suite of products and services. “Jeff’s energy, experience, and digital marketing expertise are an exciting addition to our team,” said Yext Co-Founder and CEO Howard Lerman. “His passion for connecting businesses and consumers in mutually beneficial ways…

Thomson Reuters Launches New Web-Based Continuing Education Events for Tax, Audit and Accounting Professionals

NEW YORK, June 30, 2015 – Thomson Reuters today announced the release of six new virtual conferences to help tax and accounting professionals stay abreast of new developments in the industry. The conferences offered through Checkpoint Learningwill be presented by leading AuditWatch, Gear Up and CPEasy training experts and will provide in-depth and up-to-date analysis of key issues such as health care reform, international taxation, financial reporting standards, best audit practices, and more. “We decided to develop more learning events following the positive feedback we received from the participants of last year's inaugural conferences,” said Ken Koskay, CPA, CFP, senior vice president…

Pharma Two B Announces Positive Results in its Phase IIb Pivotal Clinical Study of P2B001 for the Treatment of Early Stage Parkinson’s Disease

REHOVOT, Israel, June 30, 2015 /PRNewswire/ — Pharma Two B Ltd., a privately held company developing innovative therapeutics based on previously approved drugs, announced today the successful results of the company’s Phase IIb pivotal study of P2B001 for the treatment of early stage Parkinson’s Disease (PD). P2B001 is a combination of low dose pramipexole and low dose rasagiline administered as a proprietary sustained release formulation. The study, titled A Phase IIb, Twelve Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study, To Determine the Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects with Early Parkinson’s Disease, met primary…

Vernalis plc – Appointment of Non-Executive Director

WINNERSH, UNITED KINGDOM–(Marketwired – Jun 30, 2015) – Vernalis plc (LSE: VER) (OTC PINK: VNLPY) announces that Dr Ian David Gilham, aged 55, has been appointed to the Board as a Non-Executive Director with effect from 1 July 2015. Dr Gilham will also serve as Chairman of the Company’s Remuneration Committee. Dr Gilham has international experience in the research, development and commercialisation of diagnostic and pharmaceutical products. He is Non-Executive Chairman of a number of UK and European companies including Epistem Holdings Limited, Concepta Diagnostics Limited, Horizon Discovery Group plc, Multiplicom NV, and Biosurfit SA. Dr Gilham was formerly CEO of Axis-Sheild…

IGBT Market Worth $8,256.3 Million and Thyristor Market Worth $3,632.0 Million by 2020

DALLAS, June 30, 2015 /PRNewswire/ — According to the new market research report “IGBT Market by Packaging Type (Discrete & Module), Power Rating, & Application (Power, Renewable, Rail, UPS, EV/HEV, Motor Drive, & Consumer Electronics), & Geography, Thyristor Market by Application & Geography – Global Analysis & Forecast to 2020″, the market size of the IGBT market is expected is expected to reach $8,256.3 Million, at a CAGR of 9.5% from 2015 to 2020, whereas the market size of the thyristor market is expected to reach $3,632.0 Million, at a CAGR of 7.9% from 2015 to 2020, which includes an in-depth analysis of packaging types, power…

Oramed Enrolls First Patient in its Phase IIb Oral Insulin Study

Company’s largest study to date with over 30 clinical sites in the United States to participate JERUSALEM, June 30, 2015 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical Company focused on the development of oral drug delivery systems, announced today that the first patient has been screened in the Company’s Phase IIb trial of its oral insulin capsule, ORMD-0801.  This U.S. based study will be performed under the active Investigational New Drug (IND) application on file with the U.S. Food and Drug Administration (FDA). The Phase IIb study for type 2 diabetes is designed to generate ample data for…